BCR and cancer: Immunoregulatory pathways against cancer were significantly enriched in the low-risk group, including pathways related to antigen processing and presentation, natural killer (NK) cell-mediated cytotoxicity, T cell receptor (TCR) signaling, chemokine signaling and B cell receptor (BCR) signaling (Figure 7B).